A course designed to equip individuals implementing GCLP within laboratories handling samples from clinical trials
More informationJoin the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationGraeme McKilligan During this period where MHRA has been conducting predominantly remote inspections, we have reflected on some of the common factors in critical deficiencies we have been seeing in control strategies for cross contamination between products in shared facilities. Requirements and expectations have been refreshed with Inspectors with a particular focus of attention on sites handling products with lower level Health Based Exposure Levels (HBELs), those with products around the red area of the continuum seen in the PIC/S Q&A document,
On 07 August 2020, the OECD made OECD Draft Advisory Document on GLP Data Integrity for public comment.
In June, the Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S) issued the new document PI 052-1. What is in it?
The MHRA are planning to resume on-site UK risk-based GxP inspections in September.
ISO 14155:2020 - Clinical investigation of medical devices for human subjects — GCP Patient safety is a key focus in update of ISO 14155, the industry reference for good practice in clinical trials.
The annual metrics report for GCP referrals has now been published for 2019. In 2019, MHRA received a total of 112 serious breach notifications, of which: 75 were deemed to be a serious breach 36 deemed not to be a serious breach 1 awaiting further information to enable final determination...
EMA’s human medicines committee (CHMP) recommended eleven medicines for approval at its July 2020 meeting, including a medicine for use in countries outside the European Union.
The GLP News pages on the website have been updated today.
The European Medicines Agency has published for public consultation for a concept paper for the development of a reflection paper on criteria for the application of Article 40(5) of Regulation (EU) 2019/6.
Starting in September, MHRA is making careful preparations for a safe return to normal UK on-site inspection scheduling.